UnitedHealth expects top, bottom-line growth acceleration in next two years Says seeing steady progress across all businesses. Believes products well positioned locally. Says on-course to participate in 2 dozen state exchanges in FY15. Says consensus estimates for FY15 outlook are "well calibrated". Says "feels good" about the company's FY15 position. Expects to grow meaningfully at sustainable margins in FY15. Expects to grow earnings across the board for FY15. Says all of its businesses are better positioned for FY15 as opposed to FY14. Says Obamacare exchange business is expected to be profitable in FY15. Says Optum unit sales will be above targets. Says will grow y just under 1M Medicaid members this year. Comments made during the company's Q3 earnings conference call.
St. Jude Medical weakness a buying opportunity, says CRT Capital CRT Capital would use St. Jude Medical weakness as a buying opportunity based on accelerating EPS growth and expects CardioMEMS to be a $1B revenue opportunity over the next few years. Shares are Buy rated with a $80 price target.
Jefferies says Medtronic 'needs to do' Covidien takeover Jefferies says it "can't see how Medtronic walks" from the Covidien (COV) takeover given how compelling the merger is. The firm confirmed with Medtronic (MDT) that nothing has changed in the company's commitment to the deal since new financing terms were announced on October 3. In Jefferies view, "Medtronic needs to do this deal." It notes the spread on the acquisition widened significantly on the news that Abbvie (ABBV) is reconsidering its acquisition of Shire (SHPG).